When 4T1.2/HER2 cell-challenged mice were depleted of CD8+ T cells, they lost their tumor-regressing activity, suggesting an antitumor role of HER263–71-specific CD8+ CTLs in the control of this tumor type. This evidence concerns the gene CD8A and neoplasm.